KR20210054544A - 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 - Google Patents

포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 Download PDF

Info

Publication number
KR20210054544A
KR20210054544A KR1020217009412A KR20217009412A KR20210054544A KR 20210054544 A KR20210054544 A KR 20210054544A KR 1020217009412 A KR1020217009412 A KR 1020217009412A KR 20217009412 A KR20217009412 A KR 20217009412A KR 20210054544 A KR20210054544 A KR 20210054544A
Authority
KR
South Korea
Prior art keywords
composition
taurinamide
taurultam
dosage range
individual patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217009412A
Other languages
English (en)
Korean (ko)
Inventor
브루스 레이덴버그
로버트 디루치오
Original Assignee
코르메딕스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코르메딕스, 인코포레이티드 filed Critical 코르메딕스, 인코포레이티드
Publication of KR20210054544A publication Critical patent/KR20210054544A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217009412A 2018-08-31 2019-09-03 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료 Pending KR20210054544A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725650P 2018-08-31 2018-08-31
US62/725,650 2018-08-31
PCT/US2019/049266 WO2020047530A1 (en) 2018-08-31 2019-09-03 Taurolidine treatment for myc-expressing tumors in mammalian bodies

Publications (1)

Publication Number Publication Date
KR20210054544A true KR20210054544A (ko) 2021-05-13

Family

ID=69643283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009412A Pending KR20210054544A (ko) 2018-08-31 2019-09-03 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료

Country Status (7)

Country Link
EP (1) EP3843747A4 (https=)
JP (2) JP2021535167A (https=)
KR (1) KR20210054544A (https=)
CN (1) CN113226325A (https=)
AU (1) AU2019331913B2 (https=)
CA (1) CA3111100A1 (https=)
WO (1) WO2020047530A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
US7151099B2 (en) * 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
JP5027369B2 (ja) * 1999-12-06 2012-09-19 ガイストリッヒ ファーマ アーゲー 腫瘍を治療する方法
US20080171738A1 (en) * 2001-04-03 2008-07-17 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of Breast Cancer
US20030092707A1 (en) * 2001-10-19 2003-05-15 Redmond H. Paul Treatment of breast cancer
CA2482687C (en) * 2003-09-29 2012-11-20 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
WO2007020509A1 (en) * 2005-08-15 2007-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
CN103118669B (zh) * 2010-06-01 2016-01-13 盖斯特里希医药公司 口服药物治疗方法和组合物
EP3402527B1 (en) * 2016-01-11 2022-09-28 CorMedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
CA3018145C (en) * 2016-03-18 2024-09-17 Geistlich Pharma Ag TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
JP2021535163A (ja) * 2018-08-28 2021-12-16 コーメディクス・インコーポレーテッド タウロリジン加水分解産物による神経芽細胞腫治療

Also Published As

Publication number Publication date
JP2025128194A (ja) 2025-09-02
JP2021535167A (ja) 2021-12-16
EP3843747A4 (en) 2022-12-28
CN113226325A (zh) 2021-08-06
CA3111100A1 (en) 2020-03-05
AU2019331913B2 (en) 2025-06-26
WO2020047530A1 (en) 2020-03-05
AU2019331913A1 (en) 2021-04-29
EP3843747A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
IL269969B2 (en) 2-pmpa protrope for healthy tissue protection during imaging or radiotherapy of psma-targeted cancer
JP2015078247A (ja) 放射線療法と併用して肺癌の治療に有用なラパマイシン含有高分子ナノ粒子静脈注射用抗癌組成物
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
CN111587115A (zh) 协同癌症治疗
Tang et al. Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer
Naraharisetti et al. In vivo performance of implantable biodegradable preparations delivering Paclitaxel and Etanidazole for the treatment of glioma
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
Sapra et al. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma
KR20060061367A (ko) 디파이브로타이드를 단독으로 또는 다른 항암제들과조합하여 포함하는 항암제제
US12053478B2 (en) Taurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US20230405132A1 (en) Antitumor pharmaceutical composition and use thereof
KR20210054544A (ko) 포유류 체내의 myc-발현 종양에 대한 타우로리딘 치료
US20190381058A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
CA3008095C (en) A pharmaceutical composition comprising apatite-based matrix and surface modifying agent
KR102904381B1 (ko) 유년기 포유류 신체내의 신경모세포종을 치료하기 위한 방법 및 조성물
US20160375057A1 (en) Therapeutic compositions and methods involving cell-permeable iron
US20200375943A1 (en) Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect
EP1879597A2 (en) Lipid a analogs for treating oral and gastrointestinal mucositis
Aktaş et al. Neuroblastoma-targeted Anticancer Drug Delivery
Sadat Nanodelivery of novel inhibitors of DNA repair for enhanced cancer therapy
Soria et al. 421 A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients
McMurray et al. 422 Targeting the SH2 domain of Stat3 with phosphopeptide mimetic prodrugs leads to tumor growth inhibition and down-regulation of phosphoTyr705 Stat3 and angiogenic pathways
Lin Juan Tang, Na Wang, JingBo Wu, PeiRong Ren, JunYang Li, LiShi Yang, XiangXiang Shi, Yue Chen, ShaoZhi Fu
HK1255237B (zh) 用作强效放射敏化剂的多药组合
HK1173387A (en) Use of a rapamycin derivative for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902